« Icahn Rattles Saber at Amylin Board | Main | New Lipitor Leader in the Clubhouse -- Ranbaxy »

04/06/2012

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a0120a77f675b970b016303c4430a970d

Listed below are links to weblogs that reference WSJ Reports BMS Still Interested in Amylin:

Comments

Feed You can follow this conversation by subscribing to the comment feed for this post.

Vishal

Exenatide franchise is the key lever of Amylin’s valuation. To get the buyer and seller reconcile on the valuation , is an onerous task due to the wide gap in the peak sales estimate that one can build for a product like Bydureon. One might sound equally convincing on a $6billion peak sales estimate as someone else estimating $1billion because of the vast variety of forces that could impact the peak sales. For the large pharma companies, both global and Japanese, Cash now is a scarce asset, and with patent expiry pressure at its peak, it is unlikely that they would risk

The comments to this entry are closed.

My Photo
Blog powered by Typepad
Member since 12/2009
Bookmark and Share

April 2014

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30      

Innovate on Purpose

In the Pipeline

Life Sci VC


visited 6 states (46.1%)
Create your own visited map of Canada